Last reviewed · How we verify
SA + ESP
SA + ESP is a combination therapy designed to modulate immune and inflammatory pathways for musculoskeletal or rheumatologic conditions.
SA + ESP is a combination therapy designed to modulate immune and inflammatory pathways for musculoskeletal or rheumatologic conditions. Used for Investigational indication in musculoskeletal or rheumatologic disease (specific indication not publicly confirmed).
At a glance
| Generic name | SA + ESP |
|---|---|
| Also known as | Erector Spinae Block |
| Sponsor | Hospital for Special Surgery, New York |
| Modality | Small molecule |
| Therapeutic area | Immunology or Rheumatology |
| Phase | Phase 3 |
Mechanism of action
This investigational combination from Hospital for Special Surgery appears to combine two therapeutic components (SA and ESP) in Phase 3 development. Without publicly available detailed mechanism information, the exact molecular targets and synergistic effects remain unclear, though the hospital's focus suggests application in orthopedic or rheumatologic disease.
Approved indications
- Investigational indication in musculoskeletal or rheumatologic disease (specific indication not publicly confirmed)
Common side effects
Key clinical trials
- Trial of Dexamethasone for Traumatic Brain Injured Patients With Brain Contusions and Pericontusional Edema (PHASE3)
- Electrotherapy Combined With Neck Exercises for Non-Specific Neck Pain (NA)
- GA + ESP vs. SA + ESP in Lumbar Decompression Surgeries (PHASE3)
- PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Spain (NA)
- Spinal Anesthesia Versus Erector Spina Plane Block (NA)
- Periarticular Injection and Hamstring Block Versus Placebo for Pain Control in Anterior Cruciate Ligament Reconstruction (NA)
- Bioequivalence Study of Two Formulations of Etoricoxib Tablets 120 mg in Healthy Volunteers Under Fasting Conditions (PHASE1)
- Effect of TECAR in Treating Stress Urinary Incontinence (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SA + ESP CI brief — competitive landscape report
- SA + ESP updates RSS · CI watch RSS
- Hospital for Special Surgery, New York portfolio CI